

# INTRODUCTION

- Public insurance coverage at the time of kidney transplant (KTx), or changing from private to public insurance coverage after transplant, are associated with decreased graft survival.<sup>1-3</sup>
- KTx recipients, unlike recipients of other solid organ transplants, have historically been eligible for coverage of immunosuppressant medications for 36 months following transplant under Medicare Part B.<sup>4</sup>
- Using data from the United Network for Organ Sharing (UNOS), we tested the hypothesis that return to employment after KTx moderates the association between early Medicare exit and graft failure or mortality.

#### **MATERIALS & METHODS**

The study was deemed not human subjects research by the local IRB. Data were obtained from the UNOS registry, including follow-up through November 2020. KTx recipients aged 18 years or older from January 2005 through November 2017 were included to allow for at least 3 years of follow-up data.

The primary outcome was a composite of mortality or graft failure, conditional on 3 years of posttransplant survival with a functioning graft.

Patients were categorized into four groups: Retain Medicare Retain Medicare Exit Medicare Exit Medicare **Return to Work** No Work No Work Return to Work

Survival analysis used Kaplan-Meier curves with a log-rank test, and multivariable Cox proportional hazards models.

In the primary analysis, the insurance coverage covariate (exited Medicare coverage vs. retained coverage) was interacted with employment status to test the hypothesis that return to employment would moderate the association between Medicare exit and posttransplant outcomes.

# Exit from Medicare coverage improves outcomes among those employed after kidney transplant Jacob A. Ford, MS

### RESULTS

The sample included 45,289 patients with a median follow-up time of 7 years. Of this sample, 12,797 patients (28%) experienced death or graft failure during follow-up and 12,777 (28%) changed insurance coverage from Medicare. During the first 3 years post- transplant, 16, 673 patients participated in paid work (37%), and 23,489 achieved a functional status score of 100% (51%).



Number at risk											
Kept Medicare, no work	22586	22586	22586	22586	18661	15325	12393	9699	7341	5498	3912
Kept Medicare, resumed work	10466	10466	10466	10466	8633	7126	5707	4487	3483	2619	1839
Changed insurance, no work	6480	6480	6480	6480	5425	4520	3642	2860	2235	1711	1224
Changed insurance, resumed work	6297	6297	6297	6297	5291	4426	3593	2896	2298	1810	1383

Figure 1 compares survival outcomes by insurance coverage and work status. The log-rank tests confirmed statistically significant differences in survival across the four groups (p<0.001).

- Factors associated with increased hazard included prolonged hospital stay, acute rejection within the first year, and comorbidities of diabetes mellitus or peripheral vascular disease.
- Patients of non-Hispanic Black race faced increased hazard of mortality and graft failure compared to patients of other racial/ethnic groups.
- Donor characteristics associated with increased hazard to graft outcomes included increased donor age and non-Hispanic Black race/ethnicity.
- Factors associated with reduced hazard included pretransplant employment and an indication other than glomerular disease or tubulointerstitial disease.
- Women and patients of Hispanic/Latino ethnicity had decreased hazard to graft survival as well as receiving the kidney from a living donor.

Among patients who returned to work, a change in insurance coverage from Medicare was associated with a 7% reduction in hazard of the composite outcome of graft failure or patient mortality (HR: 0.93; 95% CI: 0.87, 0.99; p=0.024). Particularly, a change to private insurance was associated with reduced hazard of graft failure or patient mortality among those returning to work (HR: 0.89; 95% CI: 0.83, 0.96; p=0.001).



	Table 1		
Variable	HR	95% CI	P
Changed insurance coverage <sup>a</sup>	0.98	0.93, 1.03	0.484
Returned to work <sup>b</sup>	0.91	0.87, 0.96	<0.001
Changed insurance X returned to work <sup>c</sup>	0.95	0.87, 1.03	0.178
Recipient age (years)	1.00	1.00, 1.00	0.379
Recipient sex			
Male	Ref.		
Female	0.92	0.89, 0.95	<0.001
Recipient race/ethnicity			
Non-Hispanic White	Ref.		
Non-Hispanic Black	1.13	1.08, 1.18	<0.001
Hispanic/Latino	0.78	0.72, 0.82	<0.001
Other	0.81	0.74, 0.87	<0.001
Indication for transplant			
Glomerular disease	Ref.		
Tubulointerstitial disease	1.05	0.94, 1.16	0.322
Other	0.79	0.74, 0.83	<0.001
BMI (kg/m2)	1.01	1.00, 1.01	0.001
Cold ischemia time (hr)	1.00	1.00, 1.00	0.346
Hospital LOS (d)	1.002	1.001,1.003	<0.001
Acute rejection within 1 yr	1.43	1.34, 1.51	<0.001
Pretransplant diabetes	1.47	1.41, 1.53	<0.001
Pretransplant PVD	1.26	1.17, 1.35	<0.001
Pretransplant % KPS	1.00	1.00, 1.00	0.023
Educational attainment			
High school or less	Ref.		
Some college	0.99	0.94, 1.03	0.560
College degree	0.93	0.88, 0.98	0.004
Pretransplant employment	0.91	0.86, 0.95	<0.001
Donor age (years)	1.01	1.01, 1.01	<0.001
Donor sex			
Male	Ref.		
Female	1.01	0.98, 1.05	0.489
Donor race/ethnicity			
Non-Hispanic White	Ref.		
Non-Hispanic Black	1.12	1.06, 1.17	<0.001
Hispanic/Latino	0.97	0.92, 1.03	0.359
Other	1.04	0.94, 1.14	0.396
Living donor	0.81	0.76, 0.85	<0.001
Transplant year	1.00	0.99, 1.00	0.262
			<del>_</del>

Table 2									
	Variable	HR	95% CI	Р					
nodel	(a) Change in insurance among patients not working	0.98	0.93, 1.03	0.484					
	(b) Change in insurance among patients returning to work	0.93	0.87, 0.99	0.024					
	Difference between (b) and (a)	0.95	0.87, 1.03	0.178					
n - e	(c) Change to private insurance among patients not working	0.97	0.91, 1.03	0.322					
	(d) Change to other insurance among patients not working	1.00	0.93, 1.07	0.994					
	(e) Change to private insurance among patients returning to work	0.89	0.83, 0.96	0.001					
	(f) Change to other insurance among patients returning to work	1.09	0.97, 1.22	0.155					
	Difference between (e) and (c)	0.92	0.84, 1.01	0.091					
	Difference between (f) and (d)	1.09	0.95, 1.25	0.225					
nodel, by	(g) Change in insurance among patients attaining <100% KPS	0.94	0.89, 0.998	0.042					
	(h) Change in insurance among patients attaining 100% KPS	0.97	0.92, 1.02	0.289					
	Difference between (h) and (g)	1.03	0.95, 1.12	0.423					
n e, by	(i) Change to private insurance among patients attaining <100% KPS	0.91	0.85, 0.98	0.011					
	(j) Change to other insurance among patients attaining <100% KPS	1.00	0.91, 1.09	0.933					
	(k) Change to private insurance among patients attaining 100% KPS	0.93	0.87, 0.99	0.021					
	(I) Change to other insurance among patients attaining 100% KPS	1.06	0.98, 1.15	0.166					
	Difference between (k) and (i)	1.02	0.93, 1.11	0.730					
	Difference between (I) and (j)	1.06	0.94, 1.20	0.334					

## DISCUSSION

- patients returned to work.
- graft failure or mortality.
- stay insured by Medicare.
- return to work after KTx.<sup>5,6</sup>

			_	_
			$\frown$	C
				$\mathbf{\mathbf{\nabla}}$

- 418, https://doi.org/10.1093/occmed/kgz095

# ACKNOWLEDGEMENTS

This project was made possible by the Summer Scholars Research Program at the Brody School of Medicine. The project was completed by Jacob Ford under guidance from Dr. Dmitry Tumin, Dr. Hostensia Beng and Dr. Liliana Gomez Mendez.



Jacob Ford **Brody School of Medicine** East Carolina University Greenville, North Carolina 27858 fordja20@students.ecu.edu

Early exit from Medicare was favorably associated or not associated with patient and graft survival greater than 3 years after transplant, depending on whether

Patients who return to work regardless of insurance coverage type tend to have better graft survival.

• Among those returning to work, a change in insurance from Medicare is associated with reduced hazard of

This potentially demonstrates that patients able to return to employment and either gain coverage through their employer or purchase coverage individually through the marketplace have better long-term graft survival compared to patients who return to work but

Multiple studies indicate that patients who were employed prior to transplantation are most likely to

About half of patients who consider themselves able to work after KTx are employed.

1. Gill JS, Tonelli M. Penny Wise, Pound Foolish? Coverage Limits on Immunosuppression after Kidney Transplantation. New England Journal of Medicine. 2012;366(7):586-589. doi:10.1056/NEJMp1114394 2. Begaj I, Khosla S, Ray D, Sharif A. Socioeconomic deprivation is independently associated with mortality post kidney transplantation. *Kidney International*. 2013;84(4):803-809. doi:10.1038/ki.2013.176

3. Kovacs AZ, Molnar MZ, Szeifert L, et al. Sleep disorders, depressive symptoms and health-related quality of life a cross-sectional comparison between kidney transplant recipients and waitlisted patients on maintenance dialysis. Nephrology Dialysis Transplantation. 2011;26(3):1058-1065. doi:10.1093/ndt/gfq476

4. Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020, H.R.5534, 116<sup>th</sup> Congress (2020). https://www.congress.gov/bill/116th-congress/house-bill/5534

5. V D'Egidio, A Mannocci, D Ciaccio, C Sestili, R A Cocchiara, A Del Cimmuto, G La Torre, Return to work after kidney transplant: a systematic review, Occupational Medicine, Volume 69, Issue 6, August 2019, Pages 412–

6. Danuser B, Simcox A, Studer R, Koller M, Wild P, for the Psychosocial Interest Group, Swiss Transplant Cohort Study. Employment 12 months after kidney transplantation: An in-depth bio-psycho-social analysis of the Swiss Transplant Cohort. Stepkowski S, ed. PLoS ONE. 2017;12(4):e0175161. doi:10.1371/journal.pone.0175161 2. Slakey DP, Rosner M. Disability following kidney transplantation: the link to medication coverage. *Clinical Transplantation*. 2007;21(2):224-228. doi:10.1111/j.1399-0012.2006.00629.x